Celgene's Abraxane Scores a Win Against Tough Pancreatic Cancer

Celgene Corp.'s nanoparticle formulation of paclitaxel, Abraxane, when added to standard of care gemcitabine, extended the life of advanced pancreatic cancer patients by 59% at one year and more than doubled...
Source: OncologySTAT Latest News - Category: Cancer & Oncology Source Type: news